GlassScriptPhysician profile
Chad A Beeman
NPI 1700884830
$9,686.73
in general payments reported to CMS, 2019-2025
39 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,539 · 2022: $1,902 · 2023: $1,666 · 2024: $2,177 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.27 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,073.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $920.68 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $716.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $585.89 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.91 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $504.79 | 2021-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $339.90 | 2023-2025 | Voquezna |
| Abbott Laboratories | $331.77 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Corium, LLC | $326.50 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $307.33 | 2021-2024 | Trintellix |
| Sk Life Science, INC. | $280.57 | 2021-2022 | |
| Amarin Pharma, INC. | $260.73 | 2021-2022 | |
| Esperion Therapeutics, INC. | $250.00 | 2021-2024 | Nexlizet, Nexletol |
| Amgen INC. | $239.58 | 2023-2025 | Repatha, Repatha, Otezla |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Beeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.